801 related articles for article (PubMed ID: 20571060)
1. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
[TBL] [Abstract][Full Text] [Related]
2. Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis.
Engel MA; Kellermann CA; Burnat G; Hahn EG; Rau T; Konturek PC
J Physiol Pharmacol; 2010 Feb; 61(1):89-97. PubMed ID: 20228420
[TBL] [Abstract][Full Text] [Related]
3. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J
J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726
[TBL] [Abstract][Full Text] [Related]
4. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
[TBL] [Abstract][Full Text] [Related]
5. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.
Schicho R; Bashashati M; Bawa M; McHugh D; Saur D; Hu HM; Zimmer A; Lutz B; Mackie K; Bradshaw HB; McCafferty DM; Sharkey KA; Storr M
Inflamm Bowel Dis; 2011 Aug; 17(8):1651-64. PubMed ID: 21744421
[TBL] [Abstract][Full Text] [Related]
6. Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum.
Wang X; Horswill JG; Whalley BJ; Stephens GJ
Mol Pharmacol; 2011 Apr; 79(4):758-67. PubMed ID: 21189269
[TBL] [Abstract][Full Text] [Related]
7. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
[TBL] [Abstract][Full Text] [Related]
8. Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors.
Fichna J; Dicay M; Lewellyn K; Janecka A; Zjawiony JK; MacNaughton WK; Storr MA
Inflamm Bowel Dis; 2012 Jun; 18(6):1137-45. PubMed ID: 21953882
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
10. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
11. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG
J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice.
Storr MA; Bashashati M; Hirota C; Vemuri VK; Keenan CM; Duncan M; Lutz B; Mackie K; Makriyannis A; Macnaughton WK; Sharkey KA
Neurogastroenterol Motil; 2010 Jul; 22(7):787-96, e223. PubMed ID: 20180825
[TBL] [Abstract][Full Text] [Related]
13. Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice.
Ueda Y; Miyagawa N; Matsui T; Kaya T; Iwamura H
Eur J Pharmacol; 2005 Sep; 520(1-3):164-71. PubMed ID: 16153638
[TBL] [Abstract][Full Text] [Related]
14. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
[TBL] [Abstract][Full Text] [Related]
15. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin.
Hohmann AG; Farthing JN; Zvonok AM; Makriyannis A
J Pharmacol Exp Ther; 2004 Feb; 308(2):446-53. PubMed ID: 14610224
[TBL] [Abstract][Full Text] [Related]
16. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only.
Fride E; Feigin C; Ponde DE; Breuer A; Hanus L; Arshavsky N; Mechoulam R
Eur J Pharmacol; 2004 Dec; 506(2):179-88. PubMed ID: 15588739
[TBL] [Abstract][Full Text] [Related]
17. CB1-cannabinoid receptors are involved in the modulation of non-synaptic [3H]serotonin release from the rat hippocampus.
Balázsa T; Bíró J; Gullai N; Ledent C; Sperlágh B
Neurochem Int; 2008 Jan; 52(1-2):95-102. PubMed ID: 17719142
[TBL] [Abstract][Full Text] [Related]
18. Preventive and therapeutic oral administration of the pentacyclic triterpene α,β-amyrin ameliorates dextran sulfate sodium-induced colitis in mice: the relevance of cannabinoid system.
Matos I; Bento AF; Marcon R; Claudino RF; Calixto JB
Mol Immunol; 2013 Jul; 54(3-4):482-92. PubMed ID: 23454360
[TBL] [Abstract][Full Text] [Related]
19. Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.
Li XH; Lin ML; Wang ZL; Wang P; Tang HH; Lin YY; Li N; Fang Q; Wang R
Neurogastroenterol Motil; 2016 Jun; 28(6):891-9. PubMed ID: 26991932
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK.
Feng YJ; Li YY; Lin XH; Li K; Cao MH
World J Gastroenterol; 2016 Nov; 22(43):9515-9524. PubMed ID: 27920472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
